地红霉素与头孢克肟治疗慢性鼻-鼻窦炎的疗效和安全性比较
x

请在关注微信后,向客服人员索取文件

篇名: 地红霉素与头孢克肟治疗慢性鼻-鼻窦炎的疗效和安全性比较
TITLE:
摘要: 目的:比较地红霉素与头孢克肟治疗慢性鼻-鼻窦炎(CRS)的疗效和安全性。方法:149例CRS患者随机分为对照组(77例)和观察组(72例)。对照组患者给予头孢克肟分散片0.2 g,口服,每日2次,连用2周。观察组患者给予地红霉素肠溶片0.25 g,口服,每日1次,连用2周。观察两组患者的临床疗效、治疗前后体征与症状评分及不良反应发生情况。结果:观察组失访5 例,对照组失访4 例。两组患者总有效率、不良反应发生率比较,差异均无统计学意义(P>0.05);治疗后,两组患者体征与症状评分均显著低于同组治疗前,且观察组低显著于对照组,差异均有统计学意义(P<0.01)。结论 :地红霉素与头孢克肟治疗CRS的疗效和安全性均相当,但地红霉素在改善患者临床症状方面优于头孢克肟。
ABSTRACT: OBJECTIVE: To compare the efficacy and safety of dirithromycin and cefixime in the treatment of chronic rhinosinusitis (CRS). METHODS: 149 CRS patients were randomly divided into control group (77 cases) and observation group (72 cases). Control group was orally given Cefixime dispersible tablet 0.2 g, twice a day, for 2 weeks. Observation group was orally given Dirithromycin enteric-coated tablet 0.25 g, once a day, for 2 weeks. Clinical efficacy, sign and symptom score before and after treatment, and the incidence of adverse reactions in 2 groups were observed. RESULTS: There were 5 patients lost in follow-up in observation group,and 4 in control group. There were no significant differences in the total effective rate and the incidence of adverse reactions in 2 groups (P>0.05). After treatment, the sign and symptom scores in 2 groups were significantly lower than before, and observation group was lower than control group, with statistical significance (P<0.05). CONCLUSIONS: Dirithromycin and cefixime have similar efficacy and safety in the treatment of CRS, while dirithromycin is superior to cefixime in terms of improving clinical symptoms of patients.
期刊: 2017年第28卷第3期
作者: 张毅,陆海,闫瑾,郭家亮
AUTHORS: ZHANG Yi,LU Hai,YAN Jin,GUO Jialiang
关键字: 地红霉素;头孢克肟;慢性鼻-鼻窦炎;疗效;安全性
KEYWORDS: Dirithromycin; Cefixime; Chronic rhinosinusit; Efficacy; Safety
阅读数: 542 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!